Although they have known limitations,
1 spontaneous reporting pharmacovigilance databases like the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and World Health Organization VigiBase are widely cited as evidence for claims that women experience adverse drug events (ADEs) at as high as twice the rate of men.
2,3 Pharmacokinetics and pharmacodynamics are typically used to explain these sex differences
2; however, many factors could influence the distribution of ADE reports by sex, including well-known disparities in the rates at which men and women use prescribed drugs.
4 This study examined ADEs reported by sex in the FAERS database after adjusting for drug use by men and women. Information regarding how sex and gender are conceptualized in this study and its data sources appears in Supplement 1.